已收盤 11-20 16:00:00 美东时间
-0.270
-9.93%
If you had looked at Recursion Pharmaceuticals on the first trading day of 2026, with bullish analysts talking up AI driven drug discovery and bearish voices focused on cash burn and regulatory risk, it might have felt like the kind of speculative idea worth a small flutter. Holding Recursion Pharmaceuticals from the start of the year would have meant a 41.7% loss, including dividends. If that outcome stings, which early warning sign or assumptio
11-21 19:09
Recursion Pharmaceuticals reported FDA alignment on the design of its registrational Phase 3 trial for REC-4881 in familial adenomatous polyposis, including a composite event free survival primary endpoint that counts excision of adenomas 10 mm or larger across the gastrointestinal tract. The planned Phase 3 trial, informed by AI driven discovery and TUPELO data, targets a disease with no approved pharmacologic therapies and could be important fo
11-20 11:14
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
11-19 19:40
今日重点评级关注:康托·菲茨杰拉德:维持Lexeo Therapeutics"超配"评级,目标价从23美元升至37美元;摩根士丹利:维持Sana Biotechnology"超配"评级,目标价从12美元升至13美元
11-17 17:31
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $10 to $7.
11-17 02:32
The latest update is out from Recursion Pharmaceuticals ( ($RXRX) ). On Novembe...
11-03 06:24
华盛资讯11月3日讯,Recursion Pharmaceuticals, Inc. Class A公布2026财年Q3业绩,公司Q3营收0.19亿美元,同比增长258.5%,归母净利润亏损1.19亿美元,同比亏损缩窄26.6%。
11-03 06:06
华盛资讯11月3日讯,Recursion Pharmaceuticals, Inc. Class A公布2026财年Q3业绩,公司Q3营收0.19亿美元,同比增长258.5%,归母净利润亏损1.19亿美元,同比亏损缩窄26.6%。
11-03 05:48
Recursion (NASDAQ:RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2026 financial results on Monday, November 2, 2026, after the clos...
10-27 04:14
今日重点评级关注:HC Wainwright & Co.:维持Annexon"买入"评级,目标价从14美元升至25美元;HC Wainwright & Co.:维持Alto Neuroscience"买入"评级,目标价从55美元升至60美元
10-20 12:36